Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observation of Bortezomib in the Treatment of Glomerular Diseases

NCT05383547 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT05383547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05383547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observation of Bortezomib in the Treatment of Glomerular Diseases
Lead sponsor
Ruijin Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
August 2, 2022
Completion date
December 31, 2023
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bortezomib, fsgs, glomerulonephritis, iga nephropathy, mn, mpgn